New Data Backs Impact of Brainomix 360 Stroke Platform

Brainomix shared a series of new studies presented this week that validated the impact of the company’s Brainomix 360 stroke platform, including its U.S. Food and Drug Administration (FDA)-cleared Triage Stroke tool and flagship e-ASPECTS software.
 
The studies followed this week’s presentation at the European Stroke Organisation Conference (ESOC) of a groundbreaking study that involved over 80,000 patients at 26 sites over three years. This study demonstrated using Brainomix 360 Stroke was related to a further 50% increase in the number of patients getting mechanical thrombectomy and reduction in door-in-door-out (DIDO) time of about 50 minutes.
 
One multisite collaboration validated Triage Stroke as a reliable tool for detecting large vessel occlusions (LVO). When coupled with clinical information like NIHSS, the tool can help identify thrombectomy candidates, particularly those with constrained resources and basic imaging.
 
A retrospective observational study processed NCCT follow-up images with Brainomix 360 Stroke software and validated prognostic significant of automated final infarct volume (FIV) and its components. This confirmed the opportunity for artificial intelligence (AI)-derived imaging biomarkers at follow-up time points to improve randomized controlled trial design and delivery for AIS.
 
A UK study also validated e-ASPECTS software on reader performance. “e-ASPECTS is a valuable tool for clinicians in the speedy and accurate diagnosis of acute ischemic stroke (AIS), and has the potential to enable the identification of AIS patients in centres without neuroradiology expertise, improving access to life-saving treatment,” noted Dr. Anna Podlasek, lead author of the study.
 
“The studies presented this week at ESOC reflect our ongoing commitment to scientific excellence and our extensive academic collaborations with world-class research institutions, including the Mayo Clinic, the Rockefeller Institute at West Virginia University, and Boston Medical Center,” said Brainomix co-founder and CEO Dr. Michalis Papadakis. “These studies provide further validation that our AI-enabled technology can play a critical role in stroke care, helping clinicians make more confident decisions leading to more patients getting access to life-saving treatments.
 
“We are also proud to showcase the growing body of research we are conducting with Life Science partners,” Dr. Papadakis went on. “Our unique set of imaging biomarkers and clinical trial tools, along with our world-class core lab team, are delivering real value for pharma partners, device manufacturers and biotech companies, generating insights that may guide future clinical trial design.”